Related Experiment Video
Updated: May 12, 2026
12:00
Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
Forging a modern generation of polyphenol-based therapeutics
1School of Pharmacy, University of Reading, Reading, UK. b.wright@reading.ac.uk
British Journal of Pharmacology
|March 28, 2013
Summary
Polyphenols like resveratrol show promise for treating diseases, but clinical use is limited. This commentary explores how their multi-target effects can be harnessed for effective therapies.
Area of Science:
- Nutritional biochemistry and pharmacology
- Phytochemical research
- Systems pharmacology
Background:
- Polyphenols from dietary plants are investigated for health benefits, including ameliorating cancer, neurological, and cardiovascular diseases.
- Clinical application of polyphenols faces challenges like poor selectivity, dosage, toxicity, and delivery.
Purpose of the Study:
- To critique the finding that resveratrol's lack of selectivity may not hinder clinical use.
- To advance the clinical application of resveratrol.
- To integrate new findings with existing knowledge on polyphenol physiological effects.
Main Methods:
- Commentary and critique of existing research (Rieder et al.).
- Systems/network pharmacology approach.
- Analysis of polyphenol multi-target interactions.
Main Results:
- Resveratrol's lack of selectivity may not be a significant barrier to its clinical use.
- Polyphenols interact with a wide array of targets.
- Systems/network pharmacology offers a viable approach for therapeutic development.
Conclusions:
- The multi-target nature of polyphenols can be leveraged for reliable therapies.
- Systems/network pharmacology can guide the development of polyphenol-based therapeutics.
- Further research is needed to optimize resveratrol's clinical application.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...